FIELD: gene engineering.
SUBSTANCE: invention is related to protein and gene engineering and can be used in pharmaceutical industry. New options of hemostasis factor VII are proposed with high proteolytic activity as a result of replacement of amino-acid residue positioned in natural sequence as Met 298 human factor VII i.e. glutamine residue. According to invention, factor VII may include additional replacements in some other positions of proteinase domain and be represented with multi-sited mutant forms, particularly [V158T/M298Q]F-VIIa, [V158D/M298Q]F-VIIa, [V158D/E296V/M298Q]F-VIIa and [V158D/E296V/M298Q/K337A]F-VIIa. New options of factor VII are produced by recombinant DNA method. To implement this method coding nucleotide sequences, vector structures and transformed cells are proposed.
EFFECT: invention allows to use new mutant forms of factor VII for production of medicines with coagulant activity.
20 cl, 1 dwg, 2 tbl, 13 ex
